Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-27
2006-06-27
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S331000, C546S201000, C546S234000
Reexamination Certificate
active
07067534
ABSTRACT:
This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5459151 (1995-10-01), Lombardo
patent: 5563150 (1996-10-01), Curtis et al.
patent: 6365602 (2002-04-01), Bernstein et al.
patent: 6441000 (2002-08-01), Gibson et al.
patent: 6720324 (2004-04-01), Marzabadi et al.
patent: 6727264 (2004-04-01), Marzabadi
patent: 2003/0077701 (2003-04-01), Forray et al.
patent: 2004/0038855 (2004-02-01), Salon et al.
patent: 0639568 (1995-02-01), None
patent: 0659743 (1995-06-01), None
patent: WO9201672 (1992-02-01), None
patent: WO9222554 (1992-12-01), None
patent: WO9304684 (1993-03-01), None
patent: WO9533721 (1995-12-01), None
patent: WO9631508 (1996-10-01), None
patent: WO9634863 (1996-11-01), None
patent: WO9732835 (1997-09-01), None
patent: WO9741108 (1997-11-01), None
patent: WO9818071 (1998-04-01), None
patent: WO9827081 (1998-06-01), None
patent: WO9847885 (1998-10-01), None
patent: WO9959971 (1999-11-01), None
patent: WO0032582 (2000-06-01), None
patent: WO0121577 (2001-03-01), None
patent: WO0202744 (2002-01-01), None
patent: WO02/081460 (2002-10-01), None
patent: WO-02/094799 (2002-11-01), None
patent: WO-03/004027 (2003-01-01), None
Salon et al. “Human melanin concentrating . . . ” CA 136:96697 (2002).
Perez et al. “Preparation and use of aminophenyl piperazine . . . ” CA 136:325564 (2002).
Chen et al. “Preparation of substituted 3,5-dihydro-4H-imidazol-4-ones for . . . ” CA 141:123625 (2004).
Yevich et al., “Synthesis and Evaluation of N-Substituted 1-(5-Fluoro-2-Pyrimidinyl)Piperazine Derivatives as Potential Anti-Ischemic Agents”, Bioorganic & Medicinal Chemistry Letters, Aug. 25, 1994, 4(16):1941-1946.
Chemical Abstracts Registry No. 209481-69-6 CA 129:81756 (1998).
Chemical Abstracts Registry No. 183810-20-0 CA129:330740 (1998).
Chemical Abstracts Registry No. 160587-15-5 CA 122:105695 (1995).
Chemical Abstracts Registry No. 147539-58-0 CA 118:254749 (1993).
Chen Chien-An
DeLeon John E.
Jiang Yu
Lu Kai
Marzabadi Mohammad R.
Chang Celia
H. Lundbeck A/S
Kalinchak Stephen G.
LandOfFree
Substituted anilinic piperidines as MCH selective antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted anilinic piperidines as MCH selective antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted anilinic piperidines as MCH selective antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3697956